Avior Wealth Management
TRDA icon

Avior Wealth Management’s Entrada Therapeutics TRDA Stock Holding History

Avior Wealth Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4
Closed -$56 – 3612
2024
Q1 		$56 Buy
+4
New +$57 ﹤0.01% 3433

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Avior Wealth Management's TRDA Position: Q2 2024 in Review

Avior Wealth Management sold out of Entrada Therapeutics (TRDA) in Q2 2024, closing a stake of 4 shares — an estimated $56 sold.

Avior Wealth Management first reported a position in TRDA in Q1 2024 and held it in 1 quarter. The position peaked at $56 in Q1 2024. 84 funds tracked by Wall St. Rank hold TRDA as of Q2 2024.

  • Avior Wealth Management reported no remaining Entrada Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 4 Entrada Therapeutics shares in Q2 2024, an estimated $56.
  • Avior Wealth Management first reported a position in Entrada Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Entrada Therapeutics position peaked at $56 in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.